Create Account | Sign In: Author or Forum

Search Symptoms

Category: Gastroenterology | Oncology | Pharmacy | Radiology | Surgery | Conference News

Back to Journal Articles

ASCO: mFOLFIRINOX Improves Survival in Pancreatic Cancer

Last Updated: June 04, 2018.

The oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil regimen is associated with longer median disease-free and overall survival in pancreatic ductal adenocarcinoma; and, receiving chemotherapy before surgery is associated with better disease-free survival, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

MONDAY, June 4, 2018 (HealthDay News) -- The oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil (mFOLFIRINOX) regimen is associated with longer median disease-free and overall survival in pancreatic ductal adenocarcinoma; and, receiving chemotherapy before surgery is associated with better disease-free survival, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Thierry Conroy, M.D., from the Institut de Cancérologie de Lorraine in Vandœuvre-lès-Nancy, France, and colleagues randomized patients with histologically proven pancreatic ductal adenocarcinomas, 21 to 84 days after resection, to six cycles of gemcitabine (arm A; 246 patients) or 12 cycles of mFOLFIRINOX (arm B; 247 patients). The researchers found that the median disease-free survival was 12.8 and 21.6 months in arms A and B, respectively, with a median follow-up of 30.5 months (hazard ratio, 0.59). The median overall survival was 34.8 and 54.4 months in arms A and B, respectively (hazard ratio, 0.66).

Geertjan van Tienhoven, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues randomized patients with (borderline) resectable pancreatic cancer to immediate surgery (arm A; 127 patients) and preoperative chemoradiotherapy (arm B; 119 patients). The researchers found that overall survival was significantly better with preoperative chemoradiotherapy (median, 13.5 versus 17.1 months; hazard ratio, 0.71; P = 0.047). Disease-free survival was also significantly better in arm B (median, 7.9 versus 11.2 months; hazard ratio, 0.67; P = 0.010).

"This is the first randomized clinical trial to show that preoperative treatment improves outcomes for people with early stages of pancreatic cancer who can have surgery," van Tienhoven said in a statement.

Press Release - Conroy
Press Release - van Tienhoven
More Information


Previous: ASCO: Endocrine Tx Noninferior for HR+, HER2− Breast Cancer Next: Mindfulness Program May Help Increase Physical Activity Levels

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: